Suppliers / Hebei Jiheng Pharmaceutical

Hebei Jiheng Pharmaceutical

China Updated 9 July 2026

Hebei Jiheng Pharmaceutical is a contract manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 2 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 21 June 2024 as VAI.

2
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
3
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 21 June 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3004803368
Hengshui, China Not on file

What they file, and where

Molecule Regulators Docs
Acetaminophen SFDA (Saudi Arabia), US FDA 2
Folic Acid US FDA 1

Also appears on these molecule pages

Paracetamol contract manufacturing

Filings and GMP by regulator

Regulator Filings GMP certificates
MINSA (CR) 3 None
EMA None 2
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Hebei Jiheng Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 21 June 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates